ArticleMediators of inflammation2025
Detection of the Prognostic Gene CYB5D2 in Cervical Squamous Epithelial Lesions.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CYB5D2 is a novel tumor suppressor gene that exhibits ectopic expression in various tumors. This study explored its significance in cervical cancer screening and prognosis by examining its expression in cervical precancerous lesions and cancer tissues and analyzing follow-up data. CYB5D2 expression was comprehensively assessed in 112 clinical samples, combined with routine cervical cancer screening methods to evaluate its early detection potential. Postoperative survival data from cervical cancer patients were analyzed using Kaplan-Meier curves to examine the association between CYB5D2 protein expression and clinicopathological characteristics, as well as its prognostic implications. Results revealed a progressive downregulation of CYB5D2 expression with advancing cervical lesions. Immunohistochemical detection of CYB5D2 protein outperformed ThinPrep cytology test (TCT), DNA aneuploidy analysis, and HR-HPV E6/E7 mRNA testing (mRNA expression of the E6 and E7 genes in high-risk HPV virus) in diagnosing high-grade squamous intraepithelial lesions (HSIL+) of the cervix. Combined testing of TCT, HR-HPV E6/E7 mRNA, and CYB5D2 achieved 100% sensitivity and negative predictive value for HSIL+. In conclusion, low CYB5D2 expression was identified as an independent risk factor for progression-free survival (PFS) in cervical cancer patients. Incorporating CYB5D2 testing into routine screening protocols for squamous cell lesions, along with TCT and HPV testing, may enhance diagnostic efficiency and provide prognostic value for adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.